Enveric Biosciences (NASDAQ:ENVB – Get Free Report) and Zymeworks (NYSE:ZYME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Profitability
This table compares Enveric Biosciences and Zymeworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enveric Biosciences | N/A | -260.30% | -164.11% |
| Zymeworks | -179.42% | -21.97% | -17.26% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Enveric Biosciences and Zymeworks, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enveric Biosciences | 0 | 0 | 1 | 0 | 3.00 |
| Zymeworks | 0 | 1 | 3 | 0 | 2.75 |
Insider and Institutional Ownership
13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 1.2% of Enveric Biosciences shares are owned by insiders. Comparatively, 1.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Enveric Biosciences and Zymeworks”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enveric Biosciences | N/A | N/A | -$17.29 million | ($6.41) | -0.08 |
| Zymeworks | $76.01 million | 11.50 | -$118.67 million | ($1.79) | -6.87 |
Enveric Biosciences has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Enveric Biosciences has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Summary
Zymeworks beats Enveric Biosciences on 8 of the 13 factors compared between the two stocks.
About Enveric Biosciences
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
